Biotech | March 23, 2022
GMP certification for Exothera further extends its viral vector manufacturing capacity
The expansion makes Exothera one of the largest viral vector facilities in Europe
The expansion makes Exothera one of the largest viral vector facilities in Europe
Saransh Chaudhary, President, Global Critical Care Division, Venus Remedies and CEO, Venus Medicine Research Centre In conversation with Thomas C Thottathil, Editor, www.indianpharmapost.com identified key areas that the company is focusing on in its Mission 2025
New data, including two late-breaking clinical trial presentations on mavacamten and a new analysis of the GUARD-AF study, reinforce the company’s continued commitment to those living with cardiovascular disease
Hester's initial pet care portfolio will include products ranging from dermatology, grooming, anti-infective, and speciality products
Expanded capabilities across pharma services network accelerate innovation and enhance productivity for customers
Divsa's coverage across Central America bridges Barentz' leading positions in North and South America
Biolexis will also leverage the capabilities of Strides Group for launching this vaccine across regions where the group has a deep market presence and established relationships
Since 1993, Beghou Consulting has helped life sciences companies - especially emerging pharmaceutical companies - establish and manage commercial operations to better market and sell therapies
If the government feels that the industry is not complying with the uniform code, it will consider making it a statutory code
The facility registration, along with DMF registration and GMP certification provides peace of mind to clients looking to use our iPSCs for clinical and commercial use in the United States, Japan, and other global markets
Subscribe To Our Newsletter & Stay Updated
